Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;44(6):111-126.
doi: 10.1615/CritRevImmunol.2024051613.

Function of Steroid Receptor Coactivators in T Cells and Cancers: Implications for Cancer Immunotherapy

Wencan Zhang  1 , Xu Cao  2 , Hongmin Wu  1 , Xiancai Zhong  1 , Yun Shi  1 , Zuoming Sun  3
Affiliations
Review

Function of Steroid Receptor Coactivators in T Cells and Cancers: Implications for Cancer Immunotherapy

Wencan Zhang et al. Crit Rev Immunol. 2024.

Abstract

Steroid receptor coactivator (SRC) family members (SRC1, SRC2 and SRC3) are transcriptional co-regulators. SRCs orchestrate gene transcription by inducing transactivation of nuclear receptors and other transcription factors. Overexpression of SRCs is widely implicated in a range of cancers, especially hormone-related cancers. As coactivators, SRCs regulate multiple metabolic pathways involved in tumor growth, invasion, metastasis, and chemo-resistance. Emerging evidence in recent years suggest that SRCs also regulate maturation, differentiation, and cytotoxicity of T cells by controlling metabolic activities. In this review, we summarize the current understanding of the function of SRCs in T cells as well as cancer cells. Importantly, the controversies of targeting SRCs for cancer immunotherapy as well as possible reconciliation strategies are also discussed.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1.
Figure 1.
Metabolic reprogramming in T cells upon activation and differentiation. OXPHOS, oxidative phosphorylation. FAO, fatty acid oxidation.
Figure 2.
Figure 2.
Function of SRC2 in metabolic reprogramming of CD4+ and CD8+ T cells
Figure 3.
Figure 3.
Metabolic reprogramming in cancer cells
Figure 4.
Figure 4.
Function of SRCs in metabolic reprogramming of cancer cells
Figure 5.
Figure 5.
Controversies in targeting SRCs in cancer therapies
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. AL-AZAWI D, MC ILROY M, KELLY G, REDMOND A, BANE F, COCCHIGLIA S, HILL A & YOUNG LJO 2008. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. 27, 3021–3031. - PubMed
    1. ANZICK SL, KONONEN J, WALKER RL, AZORSA DO, TANNER MM, GUAN X-Y, SAUTER G, KALLIONIEMI O-P, TRENT JM & MELTZER PSJS 1997. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. 277, 965–968. - PubMed
    1. APOSTOLAKIS EM, RAMAMURPHY M, ZHOU D, OÑATE S & O’MALLEY BWJME 2002. Acute disruption of select steroid receptor coactivators prevents reproductive behavior in rats and unmasks genetic adaptation in knockout mice. 16, 1511–1523. - PubMed
    1. AUGER AP, TETEL MJ & MCCARTHY MMJPOTNAOS 2000. Steroid receptor coactivator-1 (SRC-1) mediates the development of sex-specific brain morphology and behavior. 97, 7551–7555. - PMC - PubMed
    1. BHUTIA YD, BABU E, RAMACHANDRAN S & GANAPATHY VJCR 2015. Amino acid transporters in cancer and their relevance to “glutamine addiction”: novel targets for the design of a new class of anticancer drugs. 75, 1782–1788. - PubMed

Substances